FY2024 EPS Estimates for Femasys Cut by Chardan Capital

Femasys Inc. (NASDAQ:FEMY) – Stock analysts at Chardan Capital dropped their FY2024 earnings per share estimates for Femasys in a research note issued on Wednesday, November 13th. Chardan Capital analyst K. Nakae now expects that the company will post earnings of ($0.84) per share for the year, down from their prior estimate of ($0.79). Chardan Capital currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.84) per share. Chardan Capital also issued estimates for Femasys’ FY2025 earnings at ($0.49) EPS.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Femasys in a research note on Tuesday, November 12th.

Femasys Price Performance

Shares of FEMY stock opened at $0.95 on Monday. The firm has a market cap of $21.82 million, a P/E ratio of -1.18 and a beta of -2.83. The firm has a fifty day moving average of $1.16 and a two-hundred day moving average of $1.14. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 5.93. Femasys has a 1-year low of $0.73 and a 1-year high of $2.40.

Femasys (NASDAQ:FEMY) last released its earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.04). The business had revenue of $0.55 million for the quarter, compared to analysts’ expectations of $0.40 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%.

Institutional Trading of Femasys

A number of institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC grew its position in shares of Femasys by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after buying an additional 17,473 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of Femasys by 123.9% during the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after acquiring an additional 18,004 shares during the period. Aljian Capital Management LLC acquired a new stake in shares of Femasys in the 3rd quarter worth about $27,000. Finally, CM Management LLC lifted its position in Femasys by 6.3% in the 2nd quarter. CM Management LLC now owns 425,000 shares of the company’s stock valued at $484,000 after purchasing an additional 25,000 shares during the last quarter. 65.27% of the stock is owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.